Measure of Acceptance of chRonic Visible sKin conditionS

NCT ID: NCT06103903

Last Updated: 2023-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this protocol is to validate 4 scales for evaluating the acceptance of visible chronic dermatological diseases (port wine stains, alopecia areata, vitiligo, hyperpigmentation...) with a large number of patients (children, adolescents, adults) and their parents (depending on the composition of the family cluster), in a multicentric manner (for territorial representativeness).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this protocol is to validate 4 scales for evaluating the acceptance of visible chronic dermatological diseases (port wine stains, alopecia areata, vitiligo, hyperpigmentation...) with a large number of patients (children, adolescents, adults) and their parents (depending on the composition of the family cluster), in a multicentric manner (for territorial representativeness).

The investigator will screen the patients and give them a link to complete the questionnaire (according to the age), that includes a pre-scale of acceptation of 50-55 items.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acceptance of Visible Chronic Dermatological Disease Disease Acceptance Psychological Well-Being Social Segregation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children aged 6-13 years

Children aged 6-13 years with a chronic skin visible disease

Questionnaire

Intervention Type BEHAVIORAL

Questionnaire according to age (6-13;14-17); the parents for minors and adults

Adolescents aged 14-17 years

Adolescents aged 14-17 years years with a chronic skin visible disease

Questionnaire

Intervention Type BEHAVIORAL

Questionnaire according to age (6-13;14-17); the parents for minors and adults

Adult patients

Adult patients aged 18 years and more with a chronic skin visible disease

Questionnaire

Intervention Type BEHAVIORAL

Questionnaire according to age (6-13;14-17); the parents for minors and adults

Parents of children aged 6 years and more

Parents of children aged 6 years and more with a chronic skin visible disease

Questionnaire

Intervention Type BEHAVIORAL

Questionnaire according to age (6-13;14-17); the parents for minors and adults

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire

Questionnaire according to age (6-13;14-17); the parents for minors and adults

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Targeted pathologies:

* Flat angioma
* Primary hypopigmentation and early vitiligo
* Primary hyperpigmentation
* Refractory alopecia areata or congenital alopecia
2. Persons concerned:

* Children (≥ 6 years old) suffering from one of the aforementioned pathologies
* Adults suffering from one of the above-mentioned pathologies
* Parents of children suffering from one of the aforementioned pathologies
* Parents of young adult patients if they live under the same roof
3. Oral agreement for each person (major/minor) and, where applicable, one of the holders of parental authority (minor)

Exclusion Criteria

1. Secondary "marks" (post-inflammatory, post-medication, post-traumatic, etc.)
2. Major psychiatric disorders
Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

INSERM UMR 1246 SPHERE

UNKNOWN

Sponsor Role collaborator

University Hospital, Tours

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Annabel MARUANI, MD-PhD

Role: STUDY_DIRECTOR

University Hospital of TOURS

Jean-Benoit HARDOUIN, MD-PhD

Role: STUDY_CHAIR

INSERM UMR 1246 SPHERE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital TOURS

Tours, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Annabel MARUANI, MD-PhD

Role: CONTACT

+33 (0)247479076

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Annabel MARUANI, MD-PhD

Role: primary

+33247479076

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MARKS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.